A Randomized, Double-blind, Single-dose, 2-Period, Crossover Study to Assess the Efficacy of PT027 Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult and Adolescent Subjects With Asthma
Latest Information Update: 03 Jan 2022
Price :
$35 *
At a glance
- Drugs Budesonide/salbutamol (Primary)
- Indications Asthma; Bronchoconstriction; Bronchospasm
- Focus Registrational; Therapeutic Use
- Acronyms TYREE
- Sponsors Avillion
- 23 Oct 2021 Results published in the Annals of Allergy, Asthma and Immunology
- 19 May 2021 Primary endpoint has been met (Maximum percentage fall from post-dose, pre-exercise baseline in forced expiratory volume in 1 second (FEV1) observed up to 60 minutes post-exercise challenge) , according to Results presented at the 117th International Conference of the American Thoracic Society
- 19 May 2021 Results presented at the 117th International Conference of the American Thoracic Society